6 September 2018, San Francisco: The global non-small cell lung cancer therapeutics market is expected to reach a value of USD 12.2 billion by
2025, based on a new report by Grand View Research, Inc. The non-small cell
cancer therapeutics (NSCLC) market is anticipated to witness significant growth
during the forecast period. This can be attributed to the high investment by
market players in the research and development of lung cancer therapy, presence
of a rich pipeline, and increasing penetration of drugs during the forecast
period.
Introduction of several
drugs in various geographical regions is likely to drive the market during the
forecast period. For instance, in October 2016, the FDA granted Breakthrough
Therapy Designation to Alecensa (alectinib), a drug developed by Genentech to
treat ALK-positive NSCLC as a first-line treatment. The drug has been approved
in the U.S., Japan, Canada, Hong Kong, South Korea, Kuwait, and Israel.
Presence of a strong
pipeline of drugs for non-small cell lung cancer helps propel the market during
the forecast period. Bristol-Myers Squibb Company, Orion Corporation, Merck
KGaA, AstraZeneca, F. Hoffmann-La Roche Ltd, and Pfizer, Inc. have major
molecules in the pipeline.
Access Research Report of Non-small Cell Lung Cancer
Therapeutics Market@: www.grandviewresearch.com/industry-analysis/non-small-cell-lung-cancer-nsclc-therapeutics-market
Further key findings from the study suggest:
· By drug, Alimta accounted for the highest
share in 2015. However, it is expected to witness decline in its share during
the forecast period.
· Alecensa (alectinib) is expected to grow at
the highest rate during the forecast period. This is majorly attributed to the
clinical benefit of the drug to treat ALK-positive NSCLC.
· Alecensa is expected to be a competitor to
Pfizer’s Xalkori and Merck’s Keytruda during the forecast period. A superior
progression-free survival rate of Alecensa was observed in the clinical trials
as compared to Crizotinib.
· Geographically, North America dominated the
overall industry in 2015. This is due to the early entry of drugs in the
market, increased adoption of new treatment, and high cost of the drug.
· It is expected that North America would
maintain its dominance during the forecast period and grow with the highest
rate over the coming years due to expected entry of new drugs.
· Several players are operating in the
industry. Geographical penetration and development of innovative &
effective drugs are the key strategies of the players to increase their share.
· Some of the key players are GlaxoSmithKline
(GSK) Plc., Novartis AG, AstraZeneca, F. Hoffmann-La Roche AG, Bristol-Myers
Squibb, Pfizer Inc., Eli Lilly & Company, and Sanofi.
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has
segmented the non-small cell lung cancer therapeutics market by drug and
region:
Non-small Cell Lung Cancer Therapeutics Market Drug
Outlook (Market Revenue in USD Million, 2014 - 2025)
·
Alimta
·
Iressa
·
Avastin
·
Tarceva
·
Zykadia
·
Tagrisso
·
Xalkori
·
Cyramza
·
Opdivo
·
Alecensa
Non-small Cell Lung Cancer Therapeutics Market Regional
Outlook (Market Revenue in USD Million, 2014 - 2025)
·
North America
o
U.S.
o
Canada
·
Europe
o
UK
o
Germany
·
Asia Pacific
o
Japan
o
China
·
Latin America
o
Brazil
o
Mexico
·
Middle East and Africa
o
South Africa
Access Press Release of
Non-small Cell Lung Cancer Therapeutics Market@: www.grandviewresearch.com/press-release/global-non-small-cell-lung-cancer-nsclc-therapeutics-market
About
Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports,
customized research reports, and consulting services. To help clients make
informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For
More Information: www.grandviewresearch.com
No comments:
Post a Comment